Phase 3 Peripheral Neuropathy Trial, Recruiting NCT06045013 Sponsor: General and Veteran Hospital Croatian Pride Knin Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 3 Peripheral Neuropathy Trial, Recruiting

NCT06045013
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 80 years
  • People who have been diagnosed with carpal tunnel syndrome (CTS) that has no known underlying cause (called "idiopathic" CTS)

Who may not be able to join:

  • People who have a known allergy or sensitivity to methylprednisolone (a steroid medication) or 5% dextrose (a sugar-water solution), or who have an infection or skin damage at the wrist area where the treatment would be applied
  • People who have had previous surgery on the wrist
  • People who have had a wrist injury within the last 2 years
  • People who have had an injection into the wrist within the last 6 months
  • People who have had physical therapy for their wrist within the last 6 months
  • People with a history of nerve injury in the arm or hand, a condition affecting the network of nerves in the shoulder (brachial plexopathy), severe nerve compression in the neck, or a condition where nerves or blood vessels are compressed near the collarbone (thoracic outlet syndrome)
  • People with a history of diabetes
  • People with a history of thyroid disease
  • People with a history of inflammatory joint or rheumatic disease
  • People who are pregnant
  • People who would not be able to follow the study procedures as required

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Igor Begović, MD, General and Veteran Hospital "Croatian Pride" Knin, Croatia

Phone: +385911748137

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
General and Veteran Hospital Croatian Pride Knin
Registry
ClinicalTrials.gov
Start date
13 September 2023
Est. completion
1 January 2026

Where this trial is recruiting

🇭🇷 Croatia

Primary endpoints

Pain intensity at 4 weeks post injection

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov